Cipla Quality Chemical Industries Limited(CiplaQCIL) is a pharmaceutical manufacturing company in Uganda that produces anti-retroviral, anti-malarial and Hepatitis B drugs. As of March 2019, the company’s total assets were valued at USh287.561 billion (US$78.516 million), with shareholders’ equity of USh168.310 billion (US$46 million
The share price of the firm dropped by 49 percent since it started trading on the Uganda Stock Exchange in September 2018. It fell from its initial public offering price of $0.069 per share to $0.035 per share at the end of July, recording low trading activity and low earnings to investors. Apart from the sharp drop in share prices, the company also recorded weak full-year results as of March 2019 triggering erosion of investor confidence. Profit after-tax declined by 84.8 percent to $1.79 million by the end of March 2019. Total sales revenues also declined to $51.4 million from $59.9 million reportedly due to heavy fall in procurement ordersfrom the Global Fund, the firm’s largest donor.
